166978-46-7

Basic information

• Product Name: 7-BROMO-4,4-DIMETHYL-3,4-DIHYDRO-2H-NAPHTHALEN-1-ONE
• Synonyms: 7-BROMO-4,4-DIMETHYL-3,4-DIHYDRO-2H-NAPHTHALEN-1-ONE;7-Bromo-4,4-dimethyl-1-tetralone;7-broMo-4,4-diMethyl-3,4-dihydronaphthalen-1(2H)-one;7-BroMo-3,4-dihydro-4,4-diMethylnaphthalen-1(2H)-one;7-BroMo-4,4-diMethyl-1-oxo-1,2,3,4-tetrahydronaphthalene;7-BroMo-4,4-diMethyl-3,4-dihydronaphthalen-1-one;1,2,3,4-tetrahydro-4,4-diMethyl-1-oxo-7-broMo-naphthalene
• CAS NO: 166978-46-7
• Molecular Formula: C₁₂H₁₃BrO
• Molecular Weight: 253.14
• Product Categories: Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 166978-46-7.mol

Chemical Properties

• Melting Point: 56-57 °C
• Boiling Point: 325.638 °C at 760 mmHg
• Flash Point: 68.137 °C
• Appearance: /
• Density: 1.351 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.556
• Storage Temp.: Refrigerator
• Solubility: Chloroform, Dichloromethane, Ethyl Acetate
• CAS DataBase Reference: 7-BROMO-4,4-DIMETHYL-3,4-DIHYDRO-2H-NAPHTHALEN-1-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-BROMO-4,4-DIMETHYL-3,4-DIHYDRO-2H-NAPHTHALEN-1-ONE(166978-46-7)
• EPA Substance Registry System: 7-BROMO-4,4-DIMETHYL-3,4-DIHYDRO-2H-NAPHTHALEN-1-ONE(166978-46-7)

Safety Data

• Hazardous Substances Data: 166978-46-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
7-BROMO-4,4-DIMETHYL-3,4-DIHYDRO-2H-NAPHTHALEN-1-ONE is used as an intermediate for the synthesis of high affinity retinoic acid receptor (RAR) antagonists. These antagonists are important in the development of medications targeting various diseases and conditions, such as cancer and inflammatory disorders, due to their ability to modulate gene expression and cellular differentiation.

InChI:InChI=1/C12H13BrO/c1-12(2)6-5-11(14)9-7-8(13)3-4-10(9)12/h3-4,7H,5-6H2,1-2H3

Upstream product

• 71-43-2 benzene 
• 176088-47-4 6-bromo-1,1-dimethyl-1,2,3,4-tetrahydronaphthalene 
• 166977-93-1 3,4-dihydro-4,4-dimethyl-7-amino-naphthalen-1(2H)-one 
• 7787-70-4 copper(I) bromide 
• 1426083-16-0 bis(3-bromophenyl)iodonium triflate 
• 87077-89-2 5-(3-bromophenyl)-2-methyl-2-pentanol 
• 75-09-2 dichloromethane 
• 2979-69-3 3,4-dihydro-4,4-dimethyl-1(2H)-naphthalenone 
• 3123-97-5 dihydro-5,5-dimethyl-2(3H)-furanone 

Downstream Products

• 188889-04-5 7-bromo-4,4-dimethyl-1-(p-tolyl)-1,2,3,4-tetrahydronaphthalen-1-ol 
• 188889-20-5 ethyl (E)-4-[2-(5,6,7,8-tetrahydro-5,5-dimethyl-8-oxo-2-naphthalenyl)ethenyl]-benzoate 
• 176088-49-6 6-ethynyl-4,4-dimethyl-1,2,3,4-tetrahydronaphthalene-1-one 
• 166978-48-9 7-ethynyl-3,4-dihydro-4,4-dimethylnaphthalen-1-(2H)-one 
• 166978-34-3 methyl (E)-4-(2-(5,5-dimethyl-8-oxo-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl)benzoate 
• 188887-83-4 ethyl 4-[(5,6-dihydro-5,5-dimethyl-8-(4-trifluoromethylphenyl)-2-naphthalenyl)ethynyl]benzoate 
• 180920-21-2 ethyl 4-[(5,6-dihydro-5,5-dimethyl-8-(4-(1,1-dimethylethyl)phenyl)-2-naphthalenyl)ethynyl]benzoate 
• 188887-74-3 ethyl 4-[(5,6-dihydro-5,5-dimethyl-8-(3,5-dimethylphenyl)-2-naphthalenyl)ethynyl]benzoate 
• 188887-76-5 ethyl 4-[(5,6-dihydro-5,5-dimethyl-8-(4-ethylphenyl)-2-naphthalenyl)ethynyl]benzoate 
• 188887-90-3 ethyl 4-[(5,6-dihydro-5,5-dimethyl-8-(3-hydroxyphenyl)-2-naphthalenyl)ethynyl]benzoate 
• 188887-92-5 4-[8-(4-hydroxy-phenyl)-5,5-dimethyl-5,6-dihydro-naphthalen-2-ylethynyl]-benzoic acid ethyl ester 
• 188887-81-2 ethyl 4-[(5,6-dihydro-5,5-dimethyl-8-(4-methoxyphenyl)-2-naphthalenyl)ethynyl]benzoate 

Relevant articles and documents

RETINOID COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATES THEREOF AND APPLICATION THEREOF

Disclosed are a retinoid compound, a preparation method therefor, intermediates thereof and an application thereof. The retinoid compound I of the present invention has a good tumor growth inhibition rate.

Hypervalent-Iodine-Mediated Formation of Epoxides from Carbon(sp2)-Carbon(sp3) Single Bonds

We have developed an efficient method for direct formation of epoxide groups from carbon(sp2)-carbon(sp3) single bonds of β-keto esters; the reaction is mediated by the water-soluble hypervalent iodine(V) reagent AIBX (5-trimethylammonio-1,3-dioxo-1,3-dihydro-1λ5-benzo[d][1,2]iodoxol-1-ol anion). On the basis of the results of density functional theory calculations and experimental studies, we propose that the reaction proceeds by a two-stage mechanism involving dehydrogenation of the β-keto ester substrates and epoxidation of the resulting enone intermediates. The rate-limiting step is abstraction of the β′-C-H (calculated free energy of activation, 24.5 kcal/mol).

Cu-Catalyzed cascades to carbocycles: Union of diaryliodonium salts with alkenes or alkynes exploiting remote carbocations

Copper-catalyzed cascade reactions between alkenes or alkynes and diaryliodonium salts form carbocyclic products in a single step. Arylation of the unsaturated functional group is proposed to form a carbocation intermediate that facilitates hydride shift pathways to translocate the positive charge to a remote position and enables ring formation via a Friedel-Crafts-type reaction.

Conformationally restricted novel pyrazole derivatives: Synthesis of 1,8-disubstituted 5,5-dimethyl-4,5-dihydro-1H-benzo[g]indazoles as a new class of PDE4 inhibitors

A number of novel 1,8-disubstituted 5,5-dimethyl-4,5-dihydro-1H-benzo[g] indazoles based on a conformationally restricted pyrazole framework have been designed as potential inhibitors of PDE4. All these compounds were readily prepared by using simple chem

O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity

Compounds of the formula where the symbols have the meaning described in the application, have retinoid-like or retinoid antagonist-like biological activity.

Method for inhibiting gene expression promoted by AP1 protein with RAR beta selective retinoids and method for treatment of diseases and conditions with such retinoids

Retinoid compounds which repress expression of the gene promoted by AP1 protein but which do not significantly activate expression of the genes having RA-responsive elements in their promoter region through RAR alpha and RAR GAMMA receptor subtypes, are u

High affinity retinoic acid receptor antagonists: Analogs of AGN 193109

A series of high affinity retinoic acid receptor (RAR) antagonists were prepared based upon the known antagonist AGN 193109 (2). Introduction of various phenyl groups revealed a preference for substitution at the para- position relative to the meta-site. Antagonists with the highest affinities for the RARs possessed hydrophobic groups, however, the presence of polar functionality was also well tolerated.

Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities

Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity. These assays are based on the ability of negative hormones to down-regulate the activity of chimeric retinoid receptors engineered to possess a constitutive transcription activator domain.

SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES

2,2-Dialkyl-4-aryl-substituted benzopyran and benzothiopyran derivatives of the formula STR1 where the symbols have the meaning described in the specification, have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists.

Oxime substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity

Compounds of the formula STR1 have retinoid-like or retinoid antagonist-like biological activity.